Denmark-based medical foundation Novo has used its quasi-corporate venturing unit to co-lead the £4m ($6.5m) series B round for Vantia Therapeutics, a UK-based drugs company. Venture capital (VC) firm SV Life Sciences also co-led the B round, which included VC peer MVM Life Science Partners and all existing investors in Vantia. MVM, SV and Novo…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
